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Inﬂammatory bowel disease (IBD) refers to complex chronic relapsing autoimmune disorders of the gastrointestinal
tract that have been traditionally classiﬁed into Crohn disease (CD) and ulcerative colitis (UC). We have previously
reported that genetic variation within a 250-kb haplotype (IBD5) in the 5q31 cytokine gene cluster confers sus-
ceptibility to CD in a Canadian population. In the current study, we ﬁrst replicated this association by examining
368 German trios with CD and demonstrating, by transmission/disequilibrium testing (TDT), that the same hap-
lotype is associated with CD ( ; ). Our original association study focused on the role of IBD52x p 5.97 Pp .007
in CD; we next explored the potential contribution of this locus to UC susceptibility in 187 German trios. Given
the TDT results in the present cohort with UC, IBD5 may also act as a susceptibility locus for UC ( ;2x p 8.10
). We then examined locus-locus interactions between IBD5 and CARD15, a locus reported elsewhere toPp .002
confer risk exclusively to CD. Our current results indicate that the two loci act independently to confer risk to CD
but that these two loci may behave in an epistatic fashion to promote the development of UC. Moreover, IBD5
was not associated with particular clinical manifestations upon phenotypic stratiﬁcation in the current cohort with
CD. Taken together, our results suggest that IBD5 may act as a general risk factor for IBD, with loci such as
CARD15 modifying the clinical characteristics of disease.
Inﬂammatory bowel disease (IBD) refers to a spectrum of
chronic relapsing autoimmune disorders, primarily af-
fecting the gastrointestinal tract, that have been tradi-
tionally classiﬁed into Crohn disease (CD) and ulcerative
colitis (UC). This classiﬁcation scheme is based on clin-
ical, endoscopic, radiologic, and pathologic criteria, in-
cluding the distribution of inﬂammation in the colon
and/or small intestine. Patchy transmural inﬂammation
involving any portion of the gastrointestinal tract—but
most often affecting the colon and/or the terminal por-
tion of the small intestine, termed the “ileum”—is con-
sistent with CD. In contrast, UC is restricted to the colon,
characteristically starting in the rectum and then spread-
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ing proximally in a continuous fashion with mucosal
ulcerations (Feldman and Sleisenger 1998). Signiﬁcant
variation is observed within the presentation of either
phenotypic category, which suggests that multiple sub-
types exist. Furthermore, it is clear that the current clas-
siﬁcation scheme of CD versus UC is insufﬁcient for the
subgroup of patients classiﬁed as having “indeterminate
colitis.” These patients have such a degree of overlap
between CD and UC, in terms of their clinical presen-
tation, that it is difﬁcult to conﬁdently assign them to
either category, which suggests that IBD represents a
continuum of manifestations. Epidemiologic studies have
identiﬁed a signiﬁcant genetic contribution to the etiology
of IBD. It is important that even though there are distinct
phenotypic differences between CD and UC, studies show
that relatives of persons with either CD or UC are at
increased risk for developing either form of IBD (Bonen
and Cho 2003). This suggests that, although there are
phenotype-speciﬁc susceptibility loci, some genes will be
shared by patients with CD and those with UC. The iden-
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Table 1
Frequency of Clinical Characteristics in the German Trios with UC and CD
CHARACTERISTIC
NO. (%) OF PATIENTS WITH
CD UC
CARD15nonrisk ( )anp 205 CARD15risk ( )bnp 163 CARD15nonrisk ( )cnp 152 CARD15risk ( )dnp 35
Sex (male/female) 58/147 50/113 61/91 18/17
Any history of smoking 103 (50.2) 69 (42.3) 51 (33.6) 9 (25.7)
L colonice 71 (34.6) 32 (19.6) 52 (34.2) 15 (42.9)
R colonicf 123 (60.0) 115 (70.6) 17 (11.2) 0 (0)
Colonic localizationg 41 (20.0) 26 (16.0) 83 (54.6) 20 (57.1)
Resection 102 (49.8) 94 (57.7) 14 (9.2) 5 (14.3)
Fistulization 109 (53.2) 94 (57.7) 7 (4.6) 1 (2.9)
Stenosis 117 (57.1) 100 (61.3) 15 (9.9) 5 (14.3)
Ileal 143 (69.8) 130 (79.8) 9 (5.9) 1 (2.9)
a Median age at onset 24 years.
b Median age at onset 22 years.
c Median age at onset 26 years.
d Median age at onset 23 years.
e L colonicp radiological or endoscopic evidence of disease distal to the splenic ﬂexure (descending colon, sigmoid colon, and rectum).
f R colonicp radiological or endoscopic evidence of disease proximal to splenic ﬂexure (transverse colon, ascending colon, and cecum).
g Denotes the frequency of individuals who were known to have colonic disease but had endoscopic or radiological procedures done
124 mo from the time of entry into the study or, if repeated procedures were done, there was not complete agreement as to the
anatomical localization and the extent of inﬂammation.
tiﬁcation of multiple susceptibility loci, coupled with an
understanding of how these loci interact, may aid in the
development of a molecular taxonomy of IBD to improve
treatment and outcome predictions in the disease.
We have reported elsewhere that genetic variation
within a common 250-kb haplotype in the 5q31 cytokine
gene cluster confers susceptibility to CD (Daly et al. 2001;
Rioux et al. 2001). It is estimated that two-thirds of
individuals of European-derived ancestry who have CD
harbor at least one copy of this risk haplotype. This locus,
known as “IBD5,” (MIM 606348) was ﬁrst identiﬁed
in a genomewide linkage scan of multiple families with
affected sibling pairs from a Canadian population. The
locus was of genomewide signiﬁcance in families with
early-onset CD (maximum LOD score 3.9) and of more
modest effect when all families with IBD were combined
in the analysis (maximum LOD score 2.4) (Rioux et al.
2000). As described in our previous study, a hierarchical
linkage disequilibrium (LD)–mapping strategy was em-
ployed to search for the causal genetic variation within
this 18-cM linked region. Ultimately, this approach led
to the discovery of the haplotype structure of the com-
mon variation within this locus. Speciﬁcally, this region
could be parsed into haplotype blocks that were sepa-
rated by intervals of recurrent recombination events.
Moreover, limited diversity within these haplotype blocks
(2–4 haplotypes per block accounting for 90%–98% of
all chromosomes) was observed.Multilocus analysis and
simulations deﬁned a disease risk haplotype (IBD5risk)
that extended across multiple haplotype blocks (a 250-
kb region), with signiﬁcant association with CD. Eleven
haplotype-tagging SNPs (htSNPs) were identiﬁed that
had alleles that were unique to this risk haplotype. All
11 SNPs were signiﬁcantly associated with CD (all P !
) and had essentially identical information con-.00023
tent (as a result of the very strong LD on this risk hap-
lotype) (Daly et al. 2001; Rioux et al. 2001). Any 1 of
these 11 SNPs can, therefore, act as a proxy for this risk
haplotype for the purposes of association testing (John-
son et al. 2001). Indeed, examination of the htSNPs in
a limited number of trios with CD, from an independent
Canadian population, conﬁrmed the initial observation
of association (Rioux et al. 2001).
In an effort to provide comprehensive evidence of the
replication ﬁnding for IBD5 and to gain insights into po-
tential phenotype-genotype relationships, we undertook
a study of 555 German trios with IBD. Speciﬁcally, we
examined a retrospective clinical cohort consisting of 368
patients with CD, 187 patients with UC, and their un-
affected parents, who had been recruited through the
German Crohn’s and Colitis Foundation from 1996 to
1998 (table 1). Themajority of the patientswithCD (306)
have been described elsewhere, but 62 patients with CD
have not (Hampe et al. 2002). The clinical characteristics
of the trios with UC have not been previously described.
Prior to commencing this replication study using a
single htSNP, we set out to conﬁrm that the haplotype
structure in this German cohort is equivalent to that
previously reported for the Canadian population. Spe-
ciﬁcally, 15 SNPs were genotyped in 120 German trios
with CD: 4 htSNPs and 5 non-htSNPs (that identiﬁed
both risk and nonrisk haplotypes in the 250-kb core
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Table 2
Association of the IBD5risk Haplotype in the German Cohort
with IBD
Phenotype TDT (T:U)a x2 P Group Comparisonb
IBD 292:212 12.70 .0002 NS
CD: 192:147 5.97 .0073
CARD15risk 80:61 2.56 .055 NS
CARD15nonrisk 112:86 3.41 .032
UC: 98:62 8.10 .0022
CARD15risk 24:6 10.80 .0005 !.02
CARD15nonrisk 74:56 2.49 .057
a TDT analysis performed for the IBD5 htSNP known as
“IGR2096a_1” for the A allele denoting the risk haplotype allele
(IBD5risk; T p number of transmitted chromosomes; U p number of
untransmitted chromosomes). This htSNP was genotyped in 368 trios
with CD and 187 trios with UC. Trios were stratiﬁed into groups on
the basis of the CARD15 status and IBD phenotype of the affected
child in each trio. CARD15risk denotes having at least one mutant
CARD15 allele of SNP 8, 12, or 13. CARD15nonrisk denotes being wild
type at all three variant positions.
b No statistical difference (NS) in the T:U ratios (i.e., strength of
association) of the IBD5risk haplotype observed between UC and CD,
as determined by a contingency table. There was no signiﬁcant2# 2
difference (NS) in terms of the association of IBD5risk haplotype with
CD on stratiﬁcation into CARD15risk and CARD15nonrisk subgroups by
permutation testing, but a signiﬁcant difference between these two
subgroups was observed in trios with UC ( ).P ! .02
region of association) and 6 additional SNPs to ex-
amine the structure ﬂanking this core region (3 cen-
tromeric SNPs located in the IL-4 region and 3 telo-
meric SNPs surrounding IL-3). As expected, given the
European ancestry of the two populations, we observed
an essentially identical haplotype structure in the German
chromosomes, as compared with the original Canadian
data. There was approximately the same frequency of
haplotype variants within each block between the two
populations and identical block-to-block correlations
(data not shown; analyzed as described in Daly et al.
[2001]). As a result, we were able to select a single one
of these htSNPs and to type it in the remaining IBD
samples (98.6% of the samples typed successfully). This
htSNP (known as “IGR2096a_1”) was ﬁrst identiﬁed in
our resequencing and typing of the Canadian samples;
it uniquely tags the 250-kb risk haplotype and is located
between the IRF-1 and OCTN2 genes (Rioux et al.
2001).
We ﬁrst examined the IGR2096a_1 genotype data for
evidence of overtransmission of the “A” allele, repre-
senting the risk haplotype (IBD5risk) in the 368 trios with
CD. Using the transmission/disequilibrium test (TDT)
implemented in GENEHUNTER (Daly et al. 1998), we
found that this risk allele was signiﬁcantly overtrans-
mitted from heterozygous parents to their children with
CD (192:147, transmitted:untransmitted [T:U]) giving
a x2 of 5.97 ( ; table 2). In the original asso-Pp .007
ciation study of the IBD5-risk haplotype, we had ob-
served a T:U ratio of 2.4:1 in the trios with CD. In the
smaller replication set from Quebec, reported in the same
study, we observed a ratio of 1.75:1, and, in the current
replication set, the German trios with CD have a more
modest ratio of 1.3:1. All of these observations are sta-
tistically compatible with an intermediate ratio of 1.75:
1, and the differences between these studies may be ex-
plained by a number of factors, including clinical and
genetic heterogeneity of disease, as well as statistical ﬂuc-
tuation (Glazier et al. 2002). Analysis of the German
cohort thus provides clear replication of the association
of IBD5 with disease susceptibility for CD.
IBD5 was ﬁrst identiﬁed as a CD-susceptibility locus
in our linkage study of 158 families with IBD and, sub-
sequently, in an association study that exclusively ex-
amined trios with CD (Rioux et al. 2000, 2001; Daly
et al. 2001). It should be noted, however, that the linkage
study consisted of 124 affected sibling pairs (ASPs) with
CD and 20 ASPs with UC, potentially limiting our ability
to detect linkage to UC. Considering the increased power
of association studies over linkage studies for common
alleles (Risch and Merikangas 1996), we wanted to ex-
amine the current cohort to determine if there was evi-
dence of an association of IBD5 with UC. Testing of the
IGR2096a_1 htSNP in the German trios with UC dem-
onstrated that the IBD5risk allele was signiﬁcantly over-
transmitted from heterozygous parents to affected chil-
dren, T:U ratio 98:62 ( ; ) (table 2).2x p 8.10 Pp .002
It is interesting that this result suggests, that, in fact,
IBD5risk may act as susceptibility allele not only for CD,
but also for UC. Furthermore, there is no statistical dif-
ference in the TDT ratios of the IBD5risk haplotype be-
tween the CD and UC trios, when compared by a con-
tingency table ( ), which indicates that the levelPp .32
of association of IBD5risk haplotype between CD and UC
is equivalent in this cohort.
Given the strong evidence of association of IBD5 to
CD and UC, we were interested in examining potential
locus-locus interactions with CARD15 (MIM 605956),
the other well-characterized CD locus (Hugot et al. 2001;
Ogura et al. 2001). CARD15 (also known as “NOD2”)
is believed to function in innate immunity-signaling cas-
cades involved in pathogen-associated molecular-recog-
nition pathways. Three polymorphisms in CARD15,
which occurred independently on a common haplotype,
have been associated with susceptibility to CD. These
mutations, designated “SNP8” (R702W), “SNP12”
(G908R), and “SNP13” (3020insC), yield two nonsy-
nonymous coding changes and a frameshift truncation
mutation, respectively. These three genetic variants ap-
pear to confer roughly equivalent risk, such that the
genotype relative risk for heterozygotes for any one of
these mutations ranges from ∼2-fold to 6-fold and rises
to 120-fold in homozygotes or compound heterozygotes.
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The allele frequencies of these three SNPs ranges ∼4%–
14% in the cohorts with CD who have been examined
to date (∼30%–40% of individuals with CD are het-
erozygous for at least one of these three variants) com-
pared with 1%–4% in control subjects and populations
with UC (Hampe et al. 2001; Abreu et al. 2002; Ahmad
et al. 2002; Cuthbert et al. 2002; Lesage et al. 2002;
Vermeire et al. 2002).
Interactions between IBD5 and CARD15 were, there-
fore, examined in the current cohort with IBD by strati-
fying trios into two groups on the basis of the genotypes
of the affected child. The CARD15risk group consisted
of trios with an affected child who carried at least one
copy of any of the three CARD15 mutations (R702W,
G908R, and/or 3020insC), whereas the CARD15nonrisk
group was composed of trios with an affected child bear-
ing the wild-type allele at all three variants. In trios with
CD (as seen in table 2), the IBD5risk haplotype was ov-
ertransmitted in the CARD15risk group (80:61; 2x p
; ) and in the CARD15nonrisk group (112:2.56 Pp .054
86; ; ). To assess whether there was2x p 3.41 Pp .032
a meaningful difference in the level of association of the
IBD5risk haplotype in CD on stratiﬁcation by CARD15
genotype, we performed permutation testing by randomly
assigning the CARD15 status to affected individuals in
trios. There was no statistical difference in the association
of the IBD5risk haplotype upon stratiﬁcation between the
CARDrisk and CARDnonrisk groups, which strongly sug-
gests that the two loci act in an independent fashion.
The ﬁnding that IBD5 and CARD15 act independently
to confer disease susceptibility is consistent with our re-
cent results in a smaller sample of trios with CD from
Quebec (Vermeire et al. 2002).
We next stratiﬁed trios with UC into CARD15risk and
CARD15nonrisk groups, as above. Of interest, it appeared
that the majority of the association signal of IBD5 arose
from individuals who carried the CARD15risk alleles (ta-
ble 2). The TDT ratio for IBD5risk in the CARD15risk
group was 24:6 ( ; ), compared2x p 10.80 Pp .0005
with 74:56 ( ; ) for theCARD15nonrisk2x p 2.49 Pp .057
group. As we had done for CD, we next examined
whether a signiﬁcant difference in association at IBD5
in trios with UC existed on stratiﬁcation on CARD15
alleles by permutation testing. In contrast to the case of
CD, permutation testing demonstrated that, indeed,
there was a signiﬁcant difference in association of IBD5,
on the basis of CARD15 stratiﬁcation in the cohort with
UC ( ) (table 2). One interpretation of this resultP ! .02
is that CARD15risk alleles may act in a synergistic fashion
with IBD5 to promote the development of UC, which
suggests a locus-locus interaction.
Having convincingly demonstrated a role for IBD5 in
IBD susceptibility in this population, we next examined
the role of this locus in conferring risk to intermediate
clinical phenotypes, such as disease behavior (age at on-
set, ﬁstulization, stenosis, and resection) and location
(ileal, right colonic, and left colonic) in the presence and
absence of CARD15 alleles. In terms of anatomical land-
marks, the colon can be thought of as an inverted U-
shaped organ and can be divided into right (proximal)
and left (distal), corresponding roughly to the two arms
of the U. The terminal portion of the small intestine (il-
eum) is attached to the colon at its most proximal end,
with the colon having a number of anatomically deﬁned
subdivisions, moving from right to left: ascending colonr
hepatic ﬂexurertransverse colonrsplenic ﬂexurerde-
scending colonrsigmoid colonrrectum. Disease locali-
zation was included in our analysis only if an endoscopic
or radiological study had been performed within 24 mo
of the time of entry into the study. If a procedure was
done 124 mo before, or if repeated procedures were not
in complete agreement in terms of the anatomical lo-
calization and the extent of inﬂammation, the patient
was excluded from this part of the multivariate analyses
of genotype-phenotype correlations. Eighteen percent of
individuals affected with CD and themajority of patients
with UC (55%) did not meet our stringent criteria re-
garding knowledge of stable disease localization (table
1). The latter is not surprising, considering estimates,
which suggest that the extent of disease ﬂuctuates in
20%–60% of patients with UC (Farmer et al. 1993;
Moum et al. 1996). As a result, formal analyses of ge-
notype-phenotype correlations were performed only in
trios with CD. However, given the difference in asso-
ciation of IBD5 based on CARD15 stratiﬁcation in UC,
we wanted to examine, in at least a qualitative fashion,
whether the group of individuals who comprise the
IBD5risk/CARD15risk group had some unique clinical
characteristics that correlated with their genotype status.
Only 12 individuals in this subgroup were identiﬁed as
having stable localization, but it was surprising to ﬁnd
that all 12 had inﬂammation restricted to the left colon.
This observation highlights the need, in general, to ex-
amine the role of IBD5 in a larger number of individuals
with UC.
Given the more stable nature of disease localization in
CD, a more formal analysis of these patients was pos-
sible. Univariate and multivariate analyses demonstrated
that IBD5 did not correlate with any clinical subpheno-
type of CD we examined, including age at onset, ﬁstu-
lization, stenosis, resection, and disease location (ileal,
right colonic, and left colonic) (table 3 and data not
shown). The lack of correlation of IBD5with any clinical
subphenotype that we examined in CD may, therefore,
suggest that it is a general risk factor for disease. In
contrast, these same analyses revealed a novel correla-
tion between CARD15 status and disease location. Spe-
ciﬁcally, multivariate analysis followed by stepwise re-
gression revealed that individuals with CD who carry
CARD15risk alleles have a decreased chance of having
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Table 3
Multivariate Analysis for Disease Localization in Patients with CD
Genotype Classa Ileum ORb (95% CI) Left Colon OR (95% CI) Right Colon OR (95% CI)
IBD5risk ( )np 234 1.884 (.764–4.645) 1.133 (.601–2.137) .753 (.348–1.630)
CARD15risk ( )np 146 1.130 (.657–1.942) .345c (.183–.651) 1.425 (.718–2.826)
IBD5risk/CARD15nonrisk ( )np 116 1.421 (.596–3.387) 2.954c (1.567–5.568) .644 (.318–1.304)
IBD5risk /CARD15risk ( )np 105 1.057 (.415–2.992) .426d (.217–.838) 1.392 (.661–2.935)
IBD5non-risk/ CARD15risk ( )np 11 .772 (.091–6.539) 1.267 (.270–5.945) .513 (.106–2.471)
IBD5 non-risk/CARD15nonrisk ( )np 49 .479 (.144–1.596) 1.011 (.437–2.336) 1.574 (.535–4.627)
a IBD5risk denotes having at least one copy of the risk haplotype, as assessed by the IGR2096a_1 htSNP. CARD15risk
denotes having at least one mutant CARD15 allele of SNP 8, 12, or 13. CARD15nonrisk denotes being wild type at all
three variant positions.
b The multivariate analysis with logistic regression treats the genotype of the affected individuals as the dependent
variable and the three disease localization phenotypes as three independent dichotomous variables. The OR that
was calculated compares the relative risk of individuals having, versus not having, the particular disease localization.
c P.001.
d P.05.
left colonic disease (odds ratio ; 95% CI[OR]p 0.345
0.183–0.651; ) independent of IBD5 status (seeP ! .001
table 3). Conversely, individuals who are CARD15nonrisk
have an increased chance of having left-sided disease
( ; 95% CI 1.537–5.454; ). This ef-ORp 2.89 P ! .001
fect of CARD15 on localization is independent of IBD5
status. This observation regarding left-sided disease is
also supported by univariate analysis (CARD15nonrisk)
( ; 95% CI 1.34–3.64; ).ORp 2.21 Pp .002
Most of the studies to date on genotype-phenotype
correlation related to CARD15 have not reported a mul-
tivariate analysis where the geographic site of disease
within the colon was analyzed as variable but, rather,
looked at the colonic phenotype in toto as a single in-
dependent variable (Gasche et al. 2000; Hampe et al.
2001; Abreu et al. 2002; Ahmad et al. 2002; Cuthbert
et al. 2002; Vermeire et al. 2002). However, our ﬁnding
is in agreement with the report of Lesage et al., who
reported that individuals with CARD15risk have less fre-
quent left-colon involvement at disease onset (Lesage et
al. 2002). If, indeed, the effect of CARD15risk alleles is
to protect against the development of left-sided colonic
disease while contributing to the development of gastro-
intestinal inﬂammation, this may be reﬂected in the pre-
viously perceived association of CARD15risk alleles with
ileal-right-sided disease. In fact, the study by Hampe et
al. reported an ileal association with CARD15 in a ret-
rospective cohort of 447 individuals (of which 306 are
included in the current analysis), by use of an expecta-
tion maximization algorithm (Hampe et al. 2002). A
statistically signiﬁcant association of CARD15risk alleles
with ileal disease was observed only in these same 447
individuals in the univariate analysis ( ; CIORp 2.2
0.724–3.867; ). The association of CARD15riskPp .002
with ileal disease did not stand up to testing after mul-
tivariate analysis followed by stepwise regression, but
the novel effect of CARD15 on left-sided colonic disease
remained signiﬁcant. It should be noted, however, that
even though our evidence is stronger for CARD15 hav-
ing an impact on colonic disease localization than for
its having an impact on ileal localization, either of these
observed correlations to speciﬁc intermediate disease phe-
notypes might simply be surrogates for an as-yet-uniden-
tiﬁed disease subgroup.
With the current study, we have now demonstrated in
two Canadian populations and a large German cohort
that genetic variation on the IBD5risk haplotype plays an
important role in the susceptibility to IBD. As expected
for a complex trait, IBD is believed to be the result of
a set of potentially interacting genetic susceptibility loci
and environmental factors that together inﬂuence the
clinical characteristics of the patient. The replication of
IBD5, combined with the knowledge of CARD15 ge-
notypes in the current cohort, enabled an exploration
of potential locus-locus interactions and correlation of
the loci with patient clinical characteristics. Of interest,
our results suggest that IBD5 acts independent of
CARD15 to confer susceptibility to CD, while appearing
to behave as a general risk factor in the sense that it was
not associated with any particular clinical intermediate
phenotype that we examined in the present cohort with
CD. On the other hand, CARD15, independent of IBD5,
appears to be associated with a clinical subgroup of pa-
tients (i.e., those without left-colonic disease). In con-
trast to the results in the trios with CD where there
was little evidence of a locus-locus interaction, we un-
covered a potential genetic interaction between IBD5
and CARD15 in trios with UC. Although this study
provides potential insights into IBD5 and CARD15, in
terms of locus-locus interactions and their impact on
disease subphenotypes, it is clear that additional work
will be necessary to completely characterize the inter-
actions and their inﬂuence on disease phenotype. Fur-
thermore, identiﬁcation of additional IBD loci and
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characterization of their interactions with IBD5 and
CARD15 should enable a more precise molecular clas-
siﬁcation of patients with IBD. Such a classiﬁcation
scheme, in conjunction with traditional clinical data, has
the potential for identifying patient subgroups that are
more related to disease mechanism and, therefore, may
be more powerful in diagnosis and treatment than the
current clinical classiﬁcation schemes.
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